3 completed, 2 recruiting. 3 Phase 3, 2 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 2, Recruiting 1 |
| Phase 4 | 2 | Completed 1, Recruiting 1 |
Follow FOSTER®: new trials by email Literature Review of FOSTER® trials Research Report on FOSTER®
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| BETRI-Prospective: Asthma Control in Single Inhaler ICS/LABA/LAMA (87/5/9 pMDI [BDP/FF/GB - 100/6/12.5 μg]) vs Single Inhaler ICS/LABA (200/6 pMDI [BDP/FF - 200/6 μg]) Beclometasone dipropionate, formoterol fumarate, and glycopyrronium bromide (100/6/12.5 µg per actuation), Foster® 200/6 pMDI (BDP/FF-200/6 µg) - Asthma | Phase 4 | Recruiting | Chiesi Farmaceutici S.p.A. | 644 | 2026-06-28 | 2026-07-31 |
| Beclometasone Dipropionate and Formoterol Inhalation Aerosol for Asthma Beclometasone Dipropionate and Formoterol Inhalation Aerosol, FOSTER® - Asthma (Diagnosis) | Phase 3 | Recruiting | Lunan Better Pharmaceutical Co., LTD. | 416 | 2026-06-08 | 2026-08-17 |
| CHF5993 and CHF1535 pMDI on Lung Hyperinflation and Exercise Endurance Time in Subjects With COPD CHF5993, CHF1535, Matched placebo - Chronic Obstructive Pulmonary Disease | Phase 4 | Completed | Chiesi Farmaceutici S.p.A. | 106 | 2021-10-28 | 2023-03-24 |
| Foster® pMDI (CHF 1535) Versus Symbicort® Turbohaler in COPD Patient (FORSYYN) CHF 1535 100/6 µg pMDI plus Symbicort® Turbohaler® Placebo, Symbicort® Turbohaler® plus CHF 1535 pMDI Placebo - Chronic Obstructive Pulmonary Disease | Phase 3 | Completed | Chiesi Farmaceutici S.p.A. | 750 | 2018-07-30 | 2026-05-12 |
| Efficacy of CHF1535 Via NEXT DPI Versus pMDI and BDP DPI100µg on PeakExpiratoryFlow in Asthmatic Patients CHF 1535 100/6 NEXT DPI® 2 months, CHF 1535 100/6 pMDI 2 months, BDP DPI 2 months - Asthma | Phase 3 | Completed | Chiesi Farmaceutici S.p.A. | 932 | 2011-03-01 | 2017-03-30 |
Asthma (3) · Pulmonary Disease, Chronic Obstructive (2) · Disease (1)
Chiesi Farmaceutici S.p.A. (4) · Lunan Better Pharmaceutical Co., LTD. (1)
China (2) · Bulgaria (1) · Germany (1) · Poland (1)
Henrik Watz, MD (1)
PMID 25088067, PMID 39420338, PMID 39529298
2025 (1)